NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications

Area of Science:

• Hepatology
• Immunology
• Gastroenterology

Background:

• Non-alcoholic fatty liver disease (NAFLD) affects 15-45% of the population.
• Only 10-25% of NAFLD cases progress to advanced liver disease.
• Non-alcoholic steatohepatitis (NASH) is the primary driver of fibrosis progression in NAFLD.

Purpose of the Study:

• To review the prognostic significance of liver inflammation in NAFLD.
• To explore the origins and components of inflammation in NASH.
• To discuss potential therapeutic implications for NASH treatment.

Main Methods:

• Review of existing literature on NAFLD and NASH pathogenesis.
• Analysis of inflammatory pathways and cellular components in liver injury.
• Consideration of extrahepatic sources of inflammation.

Main Results:

• Liver inflammation is a significant predictor of NAFLD progression.
• Hepatocyte injury from lipotoxicity initiates innate immune responses in NASH.
• Key inflammatory pathways include NF-κB and JNK, involving TLRs, Kupffer cells, and neutrophils.

Conclusions:

• Inflammation plays a critical role in NASH pathogenesis and progression.
• Understanding the interplay between lipotoxicity, immune activation, and signaling pathways is crucial.
• Potential therapeutic strategies may target inflammatory pathways or their upstream activators.